Interestingly, there have been low rates of pneumonitis reported (approximately <5%) in phase 1/2 studies of tarlatamab, which appears to be less than the incidence of pneumonitis typically seen with PD-L1/PD-1 inhibitors in lung cancer patients. This evidence concerns the gene CD274 and lung carcinoma.